TABLE 3.
Observation Interval (Months After Enrollment) | ||||
---|---|---|---|---|
0-6 | 6-12 | 12-24 | 24-36 | |
Patients entering observation period, n | 59 | 38 | 24 | 9 |
Outcomes during observation period among patients not completing the follow-up period, n (%) | ||||
Terminated | 17 (28.8) | 7 (18.4) | 6 25.0) | 2 22.2% |
Deceased | 1 (1.7) | - | - | - |
Use status at end of observation period,a n (%) | ||||
Unstable use | 22 (37.3) | 10 (26.3) | 3 (12.5) | 0 (0.0) |
Stable use | 18 (30.5) | 19 (50.0) | 14 (58.3) | 7 (77.8) |
Decrease/stop | 10 | 13 | 7 | 6 |
Steady use | 5 | 5 | 6 | 0 |
Maintenance replacement therapy | 3 | 1 | 1 | 1 |
Unknown | 1 (1.7) | 2 (5.3) | 1 (4.2) | - |
aThe following number of patients reached the end of the study (August 31, 2013) before the full observation interval had elapsed: 3 patients for the interval 0 to 6 months; 7 patients between 6 and 11 months; 9 patients between 12 and 23 months; and 3 patients between 24 and 36 months.